Can You Use Sublocade to Get Off Suboxone?

What Are Sublocade and Other Long-Acting Buprenorphine Injections?

Sublocade is a long-acting injectable form of buprenorphine. Instead of taking a film or tablet under the tongue every day, the patient receives a monthly injection under the skin. The medication forms a small depot, or reservoir, that slowly releases buprenorphine over time.

Sublocade is the best-known monthly injectable buprenorphine product, but it is not the only long-acting option. Brixadi is another long-acting injectable buprenorphine medication, available in weekly and monthly formulations.

These medications are FDA-approved for the treatment of moderate to severe opioid use disorder in appropriate patients who have started or are already receiving buprenorphine treatment. Their main use is ongoing treatment of opioid use disorder. But because they release medication slowly and remain in the body for a long time, they may also be useful as tapering tools for selected patients.

How Long-Acting Buprenorphine May Help With Weaning Off Suboxone

The idea is that long-acting injectable buprenorphine can act like an “ultra-slow taper.”

With daily Suboxone, patients have to manage each dose reduction. They may cut films into smaller pieces, notice every decrease, and feel the psychological weight of “going down again.” Blood levels can also rise and fall around daily dosing.

With long-acting injectable buprenorphine, medication levels are smoother. There is no daily dosing decision. After the last injection, the medication does not stop all at once. It gradually declines over weeks to months.

For some patients, this can make the taper feel less abrupt and less mentally consuming. Instead of repeatedly stepping down the dose, the patient transitions to a long-acting medication and allows the medication level to slowly fade over time.

That does not mean injectable buprenorphine makes tapering effortless. Some people still have symptoms. Some may decide they feel better continuing medication. But for the right patient, it can be a practical and thoughtful way to approach a taper that might otherwise feel very difficult.

What Does the Evidence Show?

The evidence for long-term buprenorphine treatment is much stronger than the evidence for stopping it. National guidelines do not set a maximum time limit for buprenorphine treatment, and many patients do best by continuing medication long term.

The evidence for using Sublocade or other long-acting injectable buprenorphine medications specifically to taper off Suboxone is still developing. There are published case reports and case series describing patients who used extended-release buprenorphine injections to stop sublingual buprenorphine. There are also emerging reports describing what withdrawal looks like after stopping long-acting injectable buprenorphine.

That means this is not yet a strategy supported by large, definitive clinical trials. We do not have perfect answers about who should use it, how many injections are ideal, or exactly which protocol is best.

But the approach is clinically reasonable. It fits what we know about buprenorphine pharmacology, and it matches what many clinicians see in practice: for some patients, a long-acting medication decline may be easier than repeatedly tapering small daily doses.

Who Might Be a Good Candidate?

Long-acting injectable buprenorphine as a tapering strategy tends to make the most sense for patients who are already stable on Suboxone or buprenorphine and are tapering because they want to — not because someone is pressuring them.

Good candidates usually have sustained stability, well-controlled cravings, stable housing or work, manageable mental health symptoms, and support from family, peers, counseling, recovery groups, or other meaningful recovery structures. It also helps when the patient has a realistic understanding that tapering may take time and may not be perfectly comfortable.

It is less ideal when someone has recent opioid use, recent overdose, unstable depression or anxiety, ongoing heavy alcohol or stimulant use, major life instability, or ongoing exposure to fentanyl or opioid-using environments.

A taper plan should also include a plan to restart medication if needed. Returning to buprenorphine is not failure. It is good medical care when risk returns.

Insurance and Access Limitations

One of the biggest real-world challenges is insurance coverage.

Sublocade, Brixadi, and other long-acting injectable buprenorphine medications are FDA-approved for the treatment of opioid use disorder. They are not specifically FDA-approved as a method for tapering off Suboxone.

That distinction matters. Even when the medical reasoning is sound, insurance companies may not approve long-acting injectable buprenorphine if the main goal is tapering. In practice, insurers are often more likely to approve injectable buprenorphine for patients who are struggling with adherence, continuing to relapse, or having difficulty stabilizing on daily medication. They may be less likely to approve it for someone who is doing well on Suboxone and wants to use the injection as a planned tapering strategy.

This can feel frustrating because stable patients may be exactly the people most appropriate for a thoughtful taper. But from an insurance perspective, the medication is often treated as an ongoing treatment tool rather than a discontinuation tool.

For that reason, access may depend on the patient’s insurance plan, prior authorization rules, medication history, clinical documentation, and whether the treatment is being framed as ongoing opioid use disorder care rather than simply “getting off Suboxone.”

How Shoreline Thinks About This

At Shoreline, we do not view buprenorphine as something patients must stay on forever, and we do not view stopping medication as the only sign of success.

Our goal is to help patients get their lives back. For some people, that means staying on Suboxone or buprenorphine long term because it continues to protect their stability, health, and recovery. For others, once life is more stable, it may make sense to talk about a careful taper.

Long-acting injectable buprenorphine can be a helpful tool in that conversation. It may allow selected patients to move away from daily Suboxone dosing and into a slower, smoother medication taper. The research is still early, and insurance coverage can be a barrier, but the approach is thoughtful, medically grounded, and often worth discussing for patients who are stable, motivated, and ready to consider next steps.

The safest taper is patient-driven, gradual, flexible, and medically supervised. If symptoms or cravings return, the plan should change. If restarting buprenorphine becomes the safest option, that is not going backward. It is continuing care.